MarketCap
Facebook
X
TelegramAnnual report 2025
added 11-19-2025
Enanta Pharmaceuticals Net Income 2011-2026 | ENTA
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Enanta Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -81.9 M | -116 M | -134 M | -122 M | -79 M | -36.2 M | 46.4 M | 72 M | 17.7 M | 21.7 M | 79 M | 34.4 M | 9.63 M | 21.4 M | 23.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 79 M | -134 M | -16.2 M |
Quarterly Net Income Enanta Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18.3 M | -22.6 M | -22.3 M | - | -22.7 M | -31.2 M | -33.4 M | - | -39.1 M | -37.7 M | -29 M | -95.4 M | -31.7 M | -33.6 M | -30.1 M | -54.4 M | -24 M | -22 M | -8.33 M | -8.33 M | -8.33 M | -8.33 M | 13.4 M | 13.4 M | 13.4 M | 13.4 M | 26 M | 26 M | 26 M | 26 M | 11.7 M | 36.5 M | -8.43 M | 11.7 M | -4.98 M | -1.8 M | -1.08 M | -4.98 M | 26.2 M | 5.81 M | 2.42 M | 26.2 M | 42 M | -5.04 M | 50.1 M | 42 M | -5.37 M | -4.44 M | -4.14 M | -5.37 M | 22 M | -4.05 M | -3.5 M | 32.1 M | -3.16 M | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 50.1 M | -95.4 M | -3.22 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
-33.4 M | $ 1.65 | 7.91 % | $ 92.9 M |  China |
 |
AstraZeneca PLC
AZN
|
115 M | $ 93.52 | -1.2 % | $ 96.9 B |  Britain |
 |
Autolus Therapeutics plc
AUTL
|
-221 M | $ 1.52 | -16.3 % | $ 388 M | Britain |
 |
Alterity Therapeutics Limited
ATHE
|
-12.8 M | $ 3.59 | 1.99 % | $ 8.64 B |  Australia |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B |  USA |
 |
AgeX Therapeutics
AGE
|
-14.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M |  France |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Biogen
BIIB
|
1.63 B | $ 184.48 | -1.67 % | $ 26.9 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
BioNTech SE
BNTX
|
10.3 B | $ 102.17 | 2.32 % | $ 27.2 B | Germany |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.88 M | $ 4.25 | 1.67 % | $ 9.25 B |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-384 M | $ 207.49 | 2.22 % | $ 5 B |  Danmark |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M |  Canada |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 10.84 | 0.46 % | $ 714 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-114 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Corcept Therapeutics Incorporated
CORT
|
141 M | $ 37.35 | -0.4 % | $ 3.86 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-208 M | - | - | $ 1.01 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
164 M | $ 23.18 | 2.02 % | $ 2.75 B | USA |
 |
AIkido Pharma
AIKI
|
-14.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
Celldex Therapeutics
CLDX
|
-158 M | $ 25.59 | -6.54 % | $ 1.65 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-58.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Cellectis S.A.
CLLS
|
-125 M | $ 4.22 | -4.2 % | $ 116 M | France |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | Israel |
 |
Ampio Pharmaceuticals
AMPE
|
-8.63 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
160 M | $ 29.43 | 6.09 % | $ 1.43 B | USA |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Brickell Biotech
BBI
|
-5.69 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
172 M | $ 9.66 | 2.28 % | $ 1.53 B | Britain |
 |
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-616 M | - | -6.81 % | $ 3.04 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
-1.63 M | $ 66.05 | 2.3 % | $ 8.83 B | USA |
 |
Athersys
ATHX
|
-87 M | - | 3.77 % | $ 22.4 M | USA |
 |
Avenue Therapeutics
ATXI
|
-11.7 M | - | -52.27 % | $ 4.45 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-298 M | $ 55.11 | 3.49 % | $ 4.45 B | USA |
 |
Abeona Therapeutics
ABEO
|
-54.2 M | $ 5.14 | -1.06 % | $ 110 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-366 M | $ 55.17 | 2.47 % | $ 4.65 B |  Schweiz |
 |
AVROBIO
AVRO
|
12.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
377 M | $ 632.29 | 0.09 % | $ 47.9 B | USA |
 |
ADiTx Therapeutics
ADTX
|
-40.4 M | $ 0.81 | 1.96 % | $ 10.7 K | USA |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.7 | 2.27 % | $ 17 M | USA |